1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use...

Details 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use... 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use...

2007-04-10

2007-04-10

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252100, C514S256000, C514S438000, C514S461000, C514S465000, C544S224000, C544S242000, C544S335000, C546S184000, C546S312000, C548S146000, C548S215000, C548S300100, C549S078000, C549S080000, C549S406000, C549S498000

Reexamination Certificate

active

10325087

ABSTRACT:
The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formulaor its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.

REFERENCES:
patent: 4522811 (1985-06-01), Epstein et al.
patent: 5631365 (1997-05-01), Rosenblum et al.
patent: 5767115 (1998-06-01), Rosenblum et al.
patent: 6069148 (2000-05-01), Schmidt et al.
patent: 6140343 (2000-10-01), DeNinno et al.
patent: 6147089 (2000-11-01), DeNinno et al.
patent: 6147090 (2000-11-01), DeNinno et al.
patent: 6162445 (2000-12-01), Bernardon
patent: 6197786 (2001-03-01), DeNinno et al.
patent: 6310075 (2001-10-01), DeNinno et al.
patent: 6313142 (2001-11-01), Damon et al.
patent: 0 476 658 (1992-03-01), None
patent: WO 96/08484 (1996-03-01), None
patent: WO 97/33882 (1997-09-01), None
patent: WO 98/04528 (1998-02-01), None
patent: WO 98/35937 (1998-08-01), None
patent: WO 98/40375 (1998-09-01), None
patent: WO 99/14174 (1999-03-01), None
patent: WO 99/14215 (1999-03-01), None
patent: WO 99/15504 (1999-04-01), None
patent: WO 00/17166 (2000-03-01), None
patent: WO 00/18721 (2000-04-01), None
patent: WO 00/18723 (2000-04-01), None
patent: WO 00/18724 (2000-04-01), None
patent: WO 00/38725 (2000-07-01), None
Sakharova et al., PubMed Abstract (Curr Opin Nephrol Hypertens. 10(6):727-38) Nov. 2001.
Mannino, PubMed Abstract (Respir Care 48(12):1185-91; discussion 1191-3) Dec. 2003.
Lee et al., PubMed Abstract (J Neuroimmunol. 98(2):77-88) Aug. 1999.
Corey et. al.,Tetrahedron Lett. (1972), 3769-3772.
Endo, A.J. Lipid Res. 33, 1569 (1992).
Grundy, S. M.New Engl. J. Med. 319, 24 (1988).
Jones, R. and N. Bischofberger,Antiviral Research, 27 (1995) 1-17.
Ling and Jones in “Dietary Phytosterols: A Review of Metabolism, Benefits and Side Effects,”Life Sciences, 57 (3), 195-206 (1995).
Wetterrau, et al.Science, 282, Oct. 23, 1998, pp. 751-754.
Van Dinther-Janssen, A.C.H.M. et al., “The VLA-4/VCAM-1 Pathway is Involved in Lymphocyte Adhesion to Endothelium in Rheumatoid Synovium”,Journal of Immunology, 147(12): 4207-4210, (1991).
Ohkawara, Y. et al., “In Situ Expression of the Cell Adhesion Molecules in Bronchial Tissues from Asthmatics with Air Flow Limitations: In Vivo Evidence of VCAM-1/VLA-4 Interaction in Selective Eosinophil Infiltration”,Am. J. Respir. Cell Mol. Biol., 12: 4-12 (1995).
Braunstahl, G.-J. et al., “Nasal Allergen Provocation Induces Adhesion Molecule Expression and Tissue Eosinophilia in Upper and Lower Airways”,J. Allergy Clin. Immunol., 107(3): 469-476 (2001).
Koga, M. et al., “Relationship Between Circulating Vascular Cell Adhesion Molecule-1 and Microvascular Complications in Type 2 Diabetes Mellitus”,Diabet. Med., 15: 661-667 (1998).
Wagner, O.F. et al., “Putative Role of Adhesion Molecules in Metabolic Disorders”,Horm. Metab. Res., 29: 627-630 (1997).
Jones, S.M. et al., “VCAM-1 Expression on Endothelium in Lesions from Cutaneous Lupus Erythematosus Is Increased Compared With Systemic and Localized Scleroderma”, BritishJournal of Dermatology, 135: 678-686 (1996).
Lee, S.J. et al., “Adhesion Molecule Expression and Regulation on Cells of the Central Nervous System”,Journal of Neuroimmunology, 98: 77-88 (1999).
Wasserman M.A. et al., “Chemistry and Pharmacology of Vascular Protectants: A Novel Approach to the Treatment of Atherosclerosis and Coronary Artery Disease”,American Journal of Cardiology, 91: 34A-40A (2003).

Affiliated with

Also associated with

Rating

1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3770801